HGC Investment Management’s Immunovant IMVT Stock Holding History

HGC Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-106,627	Closed	-$1.07M	–	107
2019 Q3	$1.07M	Buy	+106,627	New	+$1.05M	0.19%	61

Other funds holding IMVT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

HGC Investment Management's IMVT Position: Q4 2019 in Review

HGC Investment Management sold out of Immunovant (IMVT) in Q4 2019, closing a stake of 106,627 shares — an estimated $1.07M sold.

HGC Investment Management first reported a position in IMVT in Q3 2019 and held it in 1 quarter. The position peaked at $1.07M in Q3 2019. 24 funds tracked by Wall St. Rank hold IMVT as of Q4 2019.

HGC Investment Management reported no remaining Immunovant position as of Q4 2019 after selling out during the quarter.
HGC Investment Management sold 106,627 Immunovant shares in Q4 2019, an estimated $1.07M.
HGC Investment Management first reported a position in Immunovant in Q3 2019 and held it in 1 quarter.
HGC Investment Management's Immunovant position peaked at $1.07M in Q3 2019.
24 funds tracked by Wall St. Rank held Immunovant as of Q4 2019.

Based on HGC Investment Management's 13F filing for Q4 2019, filed 14 Feb 2020.